[1]
|
Jantchou, P., Monnet, E. and Carbonnel, F. (2006) Envi ronmetal risk factors in Crohn’s disease and ulcerative colitis (excluding tobacco and appendicectomy). Gastro entérologie Clinique et Biologique, 30, 859-867.
doi:10.1016/S0399-8320(06)73333-4
|
[2]
|
Veluswamy, H., Suryawala, K., Sheth, A., Wells, S., Salvatierra, E., Cromer, W., Chaitanya, G.V., Painter, A., Patel, M., Manas, K., Zwank, E., Boktor, M., Baig, K., Datti, B., Mathis, M.J., Minagar, A., Jordan, P.A. and Alexander, J.S. (2010) African-American inflammatory bowel disease in a Southern US health center. BMC Gastroenterology, 10, 104. doi:10.1186/1471-230X-10-104
|
[3]
|
Buhner, S., Buning, C., Genschel, J., Kling, K., Hermann, D., Dignass, A., Kuechler, I., Krueger, S., Schmidt, H.H. and Lochs, H. (2006) Genetic basis for increased intestinal permeability in families with Crohn’s disease: Role of CARD15 3020insC mutation? Gut, 55, 342-347. doi:10.1136/gut.2005.065557
|
[4]
|
Sartor, R.B. and Muehlbauer, M. (2007) Microbial host interactions in IBD: Implications for pathogenesis and therapy. Current Gastroenterology Reports, 9, 497-507.
doi:10.1007/s11894-007-0066-4
|
[5]
|
Reuter, B.K. and Pizarro, T.T. (2009) Mechanisms of tight junction dysregulation in the SAMP1/YitFc model of Crohn’s disease-like ileitis. Annals of the New York Academy of Sciences, 1165, 301-307.
doi:10.1111/j.1749-6632.2009.04035.x
|
[6]
|
Cromer, W., Jennings, M.H., Odaka, Y., Mathis, J.M. and Alexander, J.S. (2010) Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction. Microcirculation, 17, 536 547.
|
[7]
|
Podolsky, D.K. (1997) Lessons from genetic models of inflammatory bowel disease. Acta Gastroenterologica Belgica, 60, 163-165.
|
[8]
|
Laukoetter, M.G., Nava, P. and Nusrat, A. (2008) Role of the intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology, 14, 401-407.
doi:10.3748/wjg.14.401
|
[9]
|
Soriano, A., Salas, A., Salas, A., Sans, M., Gironella, M., Elena, M., Anderson, D.C., Pique, J.M. and Panes, J. (2000) VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameli rates DSS-induced colitis in mice. Laboratory Investigation, 80, 1541-1551.
doi:10.1038/labinvest.3780164
|
[10]
|
Oshima, T., Laroux, F.S., Coe, L.L., Morise, Z., Kawachi, S., Bauer, P., Grisham, M.B., Specian, R.D., Carter, P., Jennings, S., Granger, D.N., Joh, T. and Alexander, J.S. (2001) Interferon gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvascular Research, 61, 130-143.
doi:10.1006/mvre.2001.2322
|
[11]
|
Sydora, B.C., Martin, S.M., Lupicki, M., Dieleman, L.A., Doyle, J., Walker, J.W. and Fedorak, R.N. (2006) Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. Inflammatory Bowel Disease, 12, 429-436.
doi:10.1097/00054725-200606000-00001
|
[12]
|
Tellez, H.S. (2010) Digestive physiology and the role of microorganisms. Journal of Applied Poultry Research, 15, 136-144.
|
[13]
|
Madsen, K.L., Doyle, J.S., Tavernini, M.M., Jewell, L.D., Rennie, R.P. and Fedorak, R.N. (2000) Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology, 118, 1094-1105.
doi:10.1016/S0016-5085(00)70362-3
|
[14]
|
Wold, J.S. and Turnipseed, S.A. (1981) Toxicology of vancom-ycin in laboratory animals. Reviews of Infection Disease, 3, S224-S229.
doi:10.1093/clinids/3.Supplement_2.S224
|
[15]
|
Dieleman, L.A., Pena, A.S., Meuwissen, S.G. and Van Rees, E.P. (1997) Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scandanavian Journal of Gastroenterology, 223, 99-104.
|
[16]
|
Kim, H.S. and Berstad, A. (1992) Experimental colitis in animal models. Scandanavian Journal of Gastroenterology, 27, 529-537. doi:10.3109/00365529209000116
|
[17]
|
Sasaki, M., Bharwani, S., Jordan, P., Elrod, J.W., Grisham, M.B., Jackson, T.H., Lefer, D.J. and Alexander, J.S. (2003) Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radical Biology and Medicine, 35, 1679-1687.
doi:10.1016/j.freeradbiomed.2003.09.016
|
[18]
|
Sasaki, M., Bharwani, S., Jordan, P., Joh, T., Manas, K., Warren, A., Harada, H., Carter, P., Elrod, J.W., Wolcott, M., Grisham, M.B. and Alexander, J.S. (2003) The3-hy droxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. Journal of Pharmacology and Experimental Therapeutics, 305, 78-85.
doi:10.1124/jpet.102.044099
|
[19]
|
Sasaki, M., Mathis, J.M., Jennings, M.H., Jordan, P., Wang, Y., Ando, T., Joh, T. and Alexander, J.S. (2005) Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. Journal of Inflammation, 2, 13.
doi:10.1186/1476-9255-2-13
|
[20]
|
Cooper, H.S., Murthy, S.N., Shah, R.S. and Sedergran, D.J. (1993) Clinicopathologic study of dextran sulfate sodium exper mental murine colitis. Laboratory Investigation, 69, 238-249.
|
[21]
|
Grisham, M.B., Granger, D.N. and Lefer, D.J. (1998) Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: Relevance to ischemic heart disease. Free Radical Biology and Medicine, 25, 404-433. doi:10.1016/S0891-5849(98)00094-X
|
[22]
|
Hausmann, M., Obermeier, F., Paper, D.H., Balan, K., Dunger, N., Menzel, K., Falk, W., Schoelmerich, J., Herfarth, H. and Rogler, G. (2007) In vivo treatment with the herbal phenyletanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clinical & Experimental Immunology, 148, 373-381.
doi:10.1111/j.1365-2249.2007.03350.x
|
[23]
|
Arrieta, M.C., Madsen, K., Doyle, J. and Meddings, J. (2009) Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut, 58, 41-48.
doi:10.1136/gut.2008.150888
|
[24]
|
Lee, Y.T., Sung, J.J., Poon, P., Lai, K.N. and Li, P.K. (1998) Association of HLA class-II genes and anti neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. Scandanavian Journal of Gastroenterology, 33, 623-627.
doi:10.1080/00365529850171909
|
[25]
|
Mandriota, S.J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D.G., Orci, L., Alitalo, K., Christofori, G. and Pepper, M.S. (2001) Vascular endothelial growth factor-C-mediated lymphan-giogenesis promotestumour metastasis. EMBO, 20, 672-682.
doi:10.1093/emboj/20.4.672
|
[26]
|
McGuckin, M.A., Eri, R., Simms, L.A., Florin, T.H. and Radford-Smith, G. (2009) Intestinal barrier dysfunction in inflammatory bowel diseases. Inflammatory Bowel Disease, 15, 100-113. doi:10.1002/ibd.20539
|
[27]
|
Cummings, J.H., Macfarlane, G.T. and Macfarlane, S. (2003) Intestinal bacteria and ulcerative colitis. Current Issues in Intestinal Microbiology, 4, 9-20.
|
[28]
|
Dieleman, L.A., Goerres, M.S., Arends, A., Sprengers, D., Torrice, C., Hoentjen, F., Grenther, W.B. and Sartor, R.B. (2003) Lactob cillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut, 52, 370-376. doi:10.1136/gut.52.3.370
|
[29]
|
Guarner, F. and Malagelada, J.R. (2003) Role of bacteria in experimental colitis. Best Practice & Research Clinical Gatroenterology, 17, 793-804.
doi:10.1016/S1521-6918(03)00068-4
|
[30]
|
Kanauchi, O., Mitsuyama, K., Araki, Y. and Andoh, A. (2003) Modification of intestinal flora in the treatment of inflammatory bowel disease. Current Pharmaceutical Design, 9, 333-346. doi:10.2174/1381612033391883
|
[31]
|
Rath, H.C., Schultz, M., Freitag, R., Dieleman, L.A., Li, F., Linde, H.J., Scholmerich, J. and Sartor, R.B. (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infection and Immunity, 69, 2277-2285.
doi:10.1128/IAI.69.4.2277-2285.2001
|
[32]
|
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Ed berg, S. and Medzhitov, R. (2004) Recognition of com mensal micro-flora by toll-like receptors is required for intestinal home-ostasis. Cell, 118, 229-241.
doi:10.1016/j.cell.2004.07.002
|
[33]
|
Lahat, G., Halperin, D., Barazovsky, E., Shalit, I., Rabau, M., Klausner, J. and Fabian, I. (2007) Immunomodula tory effects of ciprofloxacin in TNBS-induced colitis in mice. Inflammatory Bowel Disease, 13, 557-565.
|
[34]
|
Videla, S., Vilaseca, J., Guarner, F., Salas, A., Treserra, F., Crespo, E., Antolin, M. and Malagelada, J.R. (1994) Role of Intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut, 35, 1090-1097.
doi:10.1136/gut.35.8.1090
|
[35]
|
Yigitler, C., Gulec, B., Aydogan, H., Ozcan, A., Kilinc, M., Yigit, T., Kozak, O. and Pekcan, M. (2004) Effect of mesalazine, metronidazole and gentamicin on bacterial translocation in experimental colitis. Journal of Gastroenterology and Hepatology, 19, 1179-1186.
doi:10.1111/j.1440-1746.2004.03457.x
|
[36]
|
Hans, W., Scholmerich, J., Gross, V. and Falk, W. (2000) The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. European Journal of Gastroenterology & Hepatology, 12, 267-273. doi:10.1097/00042737-200012030-00002
|
[37]
|
Kang, S.S., Bloom, S.M., Norian, L.A., Geske, M.J., Flavell, R.A., Stappenbeck, T.S. and Allen, P.M. (2008) An antibiotic responsive mouse model of fulminant ulcerative coltis. Public Library of Science Medicine, 5, e41.
|
[38]
|
Hoentjen, F., Harmsen, H.J., Braat, H., Torrice, C.D., Mann, B.A., Sartor, R.B. and Dieleman, L.A. (2003) Antibiotics with a seletive aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut, 52, 1721-1727. doi:10.1136/gut.52.12.1721
|
[39]
|
Werner, T. and Haller, D. (2007) Intestinal epithelial cell signaling and chronic inflammation: From the proteome to specific molecular mechanisms. Mutation Research, 622, 42-57. doi:10.1016/j.mrfmmm.2007.05.010
|
[40]
|
Binion, D.G., Otterson, M.F. and Rafiee, P. (2008) Curcumin inhi its VEGF-mediated angiogenesis in human intestinal mcrovascular endothelial cells through COX-2 and MAPK inhibition. Gut, 57, 1509-1517.
doi:10.1136/gut.2008.152496
|
[41]
|
Goebel, S., Huang, M., Davis, W.C., Jennings, M., Siahaan, T.J., Alexander, J.S. and Kevil, C.G. (2006) VEGF A stimulation of leukocyte adhesion to colonic microvascular endothelium: Implications for inflammatory bowel disease. American Journal of Physiology-Gastro intestinal and Liver Physology, 290, G648-G654.
|
[42]
|
Deng, X., Tolstanova, G., Khomenko, T., Chen, L., Tarnawski, A., Szabo, S. and Sandor, Z. (2009) Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: Novel molecular mechanism for therapeutic action of mesalmine. Journal of Pharmacology and Experimental Therapeutics, 331, 1071-1078.
doi:10.1124/jpet.109.158022
|
[43]
|
Ganta, V.C., Cromer, W., Mills, G.L., Traylor, J., Jennings, M., Daley, S., Clark, B., Mathis, J.M., Bernas, M., Boktor, M., Jordan, P., Witte, M. and Alexander, J.S. (2010) Angiopoietin-2 in experimental colitis. Inflammatory Bowel Disease, 16, 1029-1039.
doi:10.1002/ibd.21150
|
[44]
|
Danese, S., Sans, M., Spencer, D.M., Beck, I., Donate, F., Plunkett, M.L., de la, M.C., Redline, R., Shaw, D.E., Levine, A.D., Mazar, A.P. and Fiocchi, C. (2007) Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut, 56, 855-862.
doi:10.1136/gut.2006.114314
|